Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%
MP

Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ • Healthcare

$503.96
-$5.48 (-1.1%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$513.1
Day Range$501.81 - $515
Avg. Volume (3M)228.3K
Market Cap$11.6B
52 Week Range
$393.61$615
Next EarningsIn 33 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$364.2M100%
Gross Profitminus cost of goods$324.2M89%

In plain terms: out of every $100 in revenue, Madrigal Pharmaceuticals, Inc. currently loses $16.

Fundamentals & Financials

Revenue (TTM)
$1.2B
Net Income (TTM)
-$325M
EPS (TTM)
-$12.89
ROA (TTM)
-26.12%
Current Ratio
3.2

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-6525.0%Q1 2026-$2.57
+10.0%Q2 2026-$3.25
+25.7%Q3 2026-$1.99
Next

Nov 3

in 33 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +25.7%

Madrigal Pharmaceuticals beat consensus on both revenue and EPS in the fiscal second quarter of 2026, reported July 30, 2026. Revenue rose 71% to $364.3 million, topping the $352.1 million estimate by +3.4%, while EPS of -$1.99 topped the -$2.68 estimate by +25.7%. Gross margin held near 89% even as operating margin stayed around -16%, with operating income at about -$56.3 million and a net loss of about $57.9 million, down 37% from about $42.3 million a year ago. Operating cash flow came in at $23.3 million, and consensus for the next period calls for EPS of -$0.91 on revenue of $404.2 million.

View full earnings history

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on cardiovascular, metabolic, and liver disorders, with $958.4 million in revenue for FY2025. The company remains a clinical-stage biopharmaceutical business built around drug candidates for those disease areas and centered on therapies for metabolic and liver disease.

Name
Madrigal Pharmaceuticals, Inc.
CEO
William J. Sibold
Website
www.madrigalpharma.com
Industry
Healthcare
Employees
915

Today's Snapshot

AI-generated

The day ended with MDGL 1.1% lower at 503.96, in line with a weaker sector.

Trading Volume

Above 10d avg 243.5K

262.4K

vs S&P 500 Today

Underperforming Market

-1.27%

Updated: September 30, 2026 at 20:25 UTC

MDGL Headlines

Madrigal Pharma insiders cut stakes after earnings

March 7, 2026

4 min read
View All News

Technical Indicators

1 Buy1 Neutral6 Sell
Madrigal is under clear technical pressure: price is below the bulk of moving averages including the 200-day simple average, momentum indicators are negative with MACD and short momentum both selling, and CCI is deeply negative. ADX is muted, suggesting the move lacks strong trending breadth, while OBV shows net distribution and ATR reflects modest volatility. The pivot sits above the market and offers resistance on any bounce. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$511.91 - $524.07
    Sell
  • RSI (14)38.49
    Neutral
  • Stochastic %K (14, 3, 3)16.92
    Buy
  • MACD Level (12, 26)-5.22
    Sell

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
EXELExelixis, Inc.
$58.41-0.4%
JAZZJazz Pharmaceuticals plc
$231.52-0.4%
BAXBaxter International Inc.
$24+2.2%
BMRNBioMarin Pharmaceutical Inc.
$60+0.2%
TECHBio-Techne Corporation
$72.47+0.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.